In DLBCL/HGBL-MYC/BCL2, IGH::BCL2 fusions are the rule [20,24,40], and MYC is translocated to IG loci in 60% of the cases or to non-IG partners including BCL6, PAX5, RFTN1 and others [18,19,20,21,24]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.